C B Granger

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311, Terrace Level, Box 3850, Durham, NC 27705, USA
    Trials 14:123. 2013
  2. ncbi request reprint Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
    Christopher B Granger
    Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
    Lancet 362:772-6. 2003
  3. ncbi request reprint Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial
    Christopher B Granger
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    Circulation 108:1184-90. 2003
  4. ncbi request reprint Medication performance measures and mortality following acute coronary syndromes
    Christopher B Granger
    Duke University Medical Center, Durham, NC, USA
    Am J Med 118:858-65. 2005
  5. ncbi request reprint Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors
    C B Granger
    Duke Clinical Research Institute, Durham, NC 27710, USA
    Am Heart J 139:609-17. 2000
  6. ncbi request reprint Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries
    E M Ohman
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 84:1281-6. 1999
  7. ncbi request reprint Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators
    K W Mahaffey
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 99:2371-7. 1999
  8. ncbi request reprint Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I
    K W Mahaffey
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Circulation 97:757-64. 1998
  9. ncbi request reprint Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arte
    K W Mahaffey
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 30:1606-10. 1997
  10. ncbi request reprint Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies
    Richard E Waters
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 146:958-68. 2003

Collaborators

Detail Information

Publications135 found, 100 shown here

  1. pmc Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311, Terrace Level, Box 3850, Durham, NC 27705, USA
    Trials 14:123. 2013
    ..We evaluated alternative approaches to quantifying infarct size using CK-MB values, and the relationship between infarct size and clinical outcomes...
  2. ncbi request reprint Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
    Christopher B Granger
    Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
    Lancet 362:772-6. 2003
    ..We aimed to find out whether candesartan, an angiotensin-receptor blocker, could improve outcome in such patients not taking an ACE inhibitor...
  3. ncbi request reprint Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial
    Christopher B Granger
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    Circulation 108:1184-90. 2003
    ....
  4. ncbi request reprint Medication performance measures and mortality following acute coronary syndromes
    Christopher B Granger
    Duke University Medical Center, Durham, NC, USA
    Am J Med 118:858-65. 2005
    ..To identify patient and health care factors which are related to the use of medical treatments that comprise quality measures and to assess the relation of these measures with mortality...
  5. ncbi request reprint Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors
    C B Granger
    Duke Clinical Research Institute, Durham, NC 27710, USA
    Am Heart J 139:609-17. 2000
    ..We sought to determine the tolerability of an angiotensin II receptor blocker, candesartan cilexetil, among patients considered intolerant of ACE inhibitors...
  6. ncbi request reprint Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries
    E M Ohman
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 84:1281-6. 1999
    ..Troponin T testing could be a valuable addition to the evaluation strategy for patients with acute myocardial infarction...
  7. ncbi request reprint Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators
    K W Mahaffey
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 99:2371-7. 1999
    ..The incidence of stroke in patients with acute coronary syndromes has not been clearly defined because few trials in this patient population have been large enough to provide stable estimates of stroke rates...
  8. ncbi request reprint Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I
    K W Mahaffey
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Circulation 97:757-64. 1998
    ..Nonhemorrhagic stroke occurs in 0.1% to 1.3% of patients with acute myocardial infarction who are treated with thrombolysis, with substantial associated mortality and morbidity. Little is known about the risk factors for its occurrence...
  9. ncbi request reprint Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arte
    K W Mahaffey
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 30:1606-10. 1997
    ..This study sought to evaluate the incidence of ocular hemorrhage in patients with and without diabetes after thrombolytic therapy for acute myocardial infarction...
  10. ncbi request reprint Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies
    Richard E Waters
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 146:958-68. 2003
    ..Thus, as the reperfusion era continues to evolve, the ideal treatment strategy for patients with STEMI is being redefined to integrate pharmacologic and mechanical approaches to reperfusion...
  11. ncbi request reprint Myonecrosis after revascularization procedures
    R M Califf
    Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 31:241-51. 1998
    ..In addition, tracking of enzyme levels in clinical trials is needed to determine whether interventions that reduce periprocedural enzyme elevation also improve mortality...
  12. ncbi request reprint Bleeding in acute coronary syndromes
    Christopher B Granger
    Department of Medicine, Division of Cardiology, Duke University School of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Timely Top Med Cardiovasc Dis 10:E30. 2006
  13. ncbi request reprint Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction
    Padma Kaul
    Department of Medicine, Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 149:637-44. 2005
    ....
  14. ncbi request reprint Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trial
    K P Alexander
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 32:2023-30. 1998
    ..The purpose of this study to determine whether use of cardiac medications reflects evidence-based recommendations for patients with non-ST elevation acute coronary syndromes...
  15. ncbi request reprint Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study
    C Y Tung
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 99:370-6. 1999
    ..However, no data exist for the economic effect of stroke in the setting of acute MI (AMI). The purpose of this prospective study was to assess the effect of stroke on medical resource use and costs in AMI patients in the United States...
  16. ncbi request reprint Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes
    M C Bahit
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 37:1001-7. 2001
    ..We sought to determine the incidence of and risk factors for thrombotic events early after discontinuing antithrombin therapy in patients with acute coronary syndromes...
  17. ncbi request reprint Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries
    B S Crenshaw
    Duke Clinical Research Institute, Durham, North Carolina
    J Am Coll Cardiol 30:406-13. 1997
    ..We examined the clinical predictors and angiographic and clinical outcomes associated with atrial fibrillation in the setting of acute myocardial infarction (MI)...
  18. ncbi request reprint Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators
    L K Newby
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 98:1853-9. 1998
    ....
  19. ncbi request reprint Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries
    R D Anderson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 30:708-15. 1997
    ..We sought to examine the use, complications and outcomes with early intraaortic balloon counterpulsation (IABP) in patients presenting with cardiogenic shock complicating acute myocardial infarction and treated with thrombolytic therapy...
  20. ncbi request reprint Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I and III trials. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries
    M G Cohen
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 34:1729-37. 1999
    ..We sought to describe the differences in the process of care and clinical outcomes between Hispanics and non-Hispanics receiving thrombolytic therapy for myocardial infarction (MI)...
  21. doi request reprint Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin
    E Marc Jolicoeur
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 104:292-7. 2009
    ..77, 95% confidence interval 1.67 to 4.61, respectively). In conclusion, medical management should be directed mainly at the prevention of thromboembolic complications, while additionally considering the risk for bleeding...
  22. ncbi request reprint Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction
    Manesh R Patel
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 151:316-22. 2006
    ..Cardiac tamponade is a life-threatening complication of acute myocardial infarction (MI). Data on the incidence, risk factors, and outcome of tamponade in patients with acute MI in the fibrinolytic era are limited...
  23. pmc Peakwide mapping on chromosome 3q13 identifies the kalirin gene as a novel candidate gene for coronary artery disease
    Liyong Wang
    Center for Human Genetics, Department of Medicine, Duke Univeristy Medical Center, Durham, NC, USA
    Am J Hum Genet 80:650-63. 2007
    ..KALRN and two other associated genes identified in this study (CDGAP and MYLK) belong to the Rho GTPase-signaling pathway. Our data suggest the importance of the KALRN gene and the Rho GTPase-signaling pathway in the pathogenesis of CAD...
  24. ncbi request reprint Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial)
    Manesh R Patel
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 95:614-8. 2005
    ..Baseline and serial measurements of WBC counts and temperature were correlated with infarct size and clinical outcome...
  25. ncbi request reprint Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III
    M P Hudson
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 104:1229-35. 2001
    ....
  26. ncbi request reprint Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial)
    David E Kandzari
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 93:458-61. 2004
    ..4, 95% confidence interval 1.2 to 10.2). Because facial or head trauma may greatly influence treatment decisions, this risk factor should be incorporated into models designed to estimate the risks and benefits of fibrinolytic therapy...
  27. ncbi request reprint Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopen
    E Magnus Ohman
    Division of Cardiology, Division of Hematology, and School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599 7075, USA
    J Thromb Thrombolysis 19:11-9. 2005
    ..Both HIT and HITT are associated with high morbidity and mortality and represent substantial worldwide public health concerns...
  28. doi request reprint Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension (STAT) registry
    Jason N Katz
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 158:599-606.e1. 2009
    ..Limited data are available on the care of patients with acute severe hypertension requiring hospitalization. We characterized contemporary practice patterns and outcomes for this population...
  29. pmc GATA2 is associated with familial early-onset coronary artery disease
    Jessica J Connelly
    Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, North Carolina, United States
    PLoS Genet 2:e139. 2006
    ....
  30. ncbi request reprint Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis. Reexamining the "gold standard" for myocardial reperfusion assessment
    A Shah
    Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 35:666-72. 2000
    ....
  31. ncbi request reprint Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion
    M T Roe
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 37:9-18. 2001
    ..Thus, as the reperfusion era moves into the next millennium, the open-artery hypothesis is expected to shift downstream and guide efforts to further improve myocardial salvage and clinical outcomes after acute MI...
  32. ncbi request reprint Reperfusion strategies for acute myocardial infarction in the elderly: benefits and risks
    Rajendra H Mehta
    Duke Clinical Research Institute and Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 45:471-8. 2005
    ..Clearly targeted large-scale clinical trials are needed to evaluate the relative merits of available reperfusion strategies as well as newer antithrombotic adjunctive therapies in the elderly with STEMI...
  33. ncbi request reprint Reducing cardiac events after acute coronary syndromes
    Christopher B Granger
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Rev Cardiovasc Med 5:S39-46. 2004
    ....
  34. ncbi request reprint Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes
    Rajendra H Mehta
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27710, USA
    JAMA 293:1746-50. 2005
    ..Incorrect dosing of alteplase has been associated with worse clinical outcomes in patients. However, patients at high risk of adverse events are more prone to dosing errors, thus confounding this relationship...
  35. ncbi request reprint Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention
    Peter R Sinnaeve
    Duke Clinical Research Center, Durham, NC, USA
    Eur Heart J 26:2396-403. 2005
    ..heparin...
  36. ncbi request reprint Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials
    John M Galla
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 151:16-24. 2006
    ..A concomitant goal was to contribute insight to the debate over how patients with NSTE ACS should be managed...
  37. doi request reprint Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomes
    Jason N Katz
    Department of Medicine, Division of Cardiology and Pulmonary and Critical Care Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Crit Care Med 38:375-81. 2010
    ..To describe long-term temporal trends in patient characteristics, processes of care, and in-hospital outcomes among unselected admissions within the contemporary coronary care unit...
  38. doi request reprint Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Med 123:134-40. 2010
    ....
  39. ncbi request reprint Thresholds for the electrocardiographic change range of biochemical markers of acute myocardial infarction (GUSTO-IIa data)
    Maria Cecilia Bahit
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 90:233-7. 2002
    ..8 (upper limit of normal 1.5 ng/ml). This study revealed that 95% of the patients with definite ECG evidence of AMI had a more than twofold increase in CK-MB and more than a 3- to 11-fold increase in troponin...
  40. doi request reprint Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 159:331-9. 2010
    ....
  41. ncbi request reprint Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries
    Ian C Gilchrist
    Division of Cardiology, Department of Medicine, Pennsylvania State University, Hershey, PA, USA
    Am Heart J 144:73-80. 2002
    ..This study analyzed relationships among heparin dosage, patient characteristics, and 30-day outcome because optimal unfractionated-heparin dosing in acute coronary syndromes remains uncertain...
  42. ncbi request reprint The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events
    L Kristin Newby
    Duke Clinical Research Institute, Durham, North Carolina 27707, USA
    Am J Med 112:647-58. 2002
    ..To understand these findings, we performed a meta-analysis of results from four phase 3 trials...
  43. ncbi request reprint Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma
    Mark P Donahue
    Duke University Medical Center and the Duke Clinical Research Institute, Durham, NC 27710, USA
    Am Heart J 152:478-85. 2006
    ..Relating a disease state to an entire population of proteins provides an opportunity to gain new insights into a disease...
  44. ncbi request reprint Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes
    Sunil V Rao
    The Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 96:1200-6. 2005
    ..Therapies that minimize bleeding risk and maintain an anticoagulant effect may improve outcomes among patients who have ACS...
  45. ncbi request reprint A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes
    Sunil V Rao
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 47:809-16. 2006
    ..The goal of this study was to determine the association between Thrombolysis In Myocardial Infarction (TIMI) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) bleeding and clinical outcomes...
  46. ncbi request reprint Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 152:291-6. 2006
    ....
  47. ncbi request reprint Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft
    Rajendra H Mehta
    Division of Cardiology, Department of Internal Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA
    Circulation 114:I396-401. 2006
    ..The influence of an internal mammary artery (IMA) graft on long-term outcomes after percutaneous saphenous vein graft (SVG) intervention is currently unknown...
  48. ncbi request reprint Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial
    Bradi B Granger
    Duke University Medical Center and Duke University School of Nursing, Durham, NC, USA
    Lancet 366:2005-11. 2005
    ....
  49. ncbi request reprint Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study
    Abhinav Goyal
    Duke Clinical Research Institute and Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    Eur Heart J 27:1289-97. 2006
    ..We evaluated the prognostic significance of baseline glucose and the change in glucose in the first 24 h following AMI...
  50. ncbi request reprint The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction
    Rajendra H Mehta
    Duke Clinical Research Institute and Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA, and Greenlane Cardiovascular Service, Auckland City Hospital, New Zealand
    Eur Heart J 28:415-24. 2007
    ..However, the relative prognostic importance of these measures over other baseline variables is less known...
  51. ncbi request reprint Reperfusion of acute myocardial infarction in North Carolina emergency departments (RACE): study design
    James G Jollis
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 152:851.e1-11. 2006
    ....
  52. doi request reprint Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am J Med 124:48-57. 2011
    ....
  53. pmc Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Crit Care Med 39:78-83. 2011
    ..The objective of this analysis was to describe the survival of patients with sustained ventricular tachycardia/ventricular fibrillation after myocardial infarction according to antiarrhythmic drug treatment...
  54. doi request reprint Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease
    Svati H Shah
    Duke University Medical Center, Durham, NC, USA
    Am Heart J 160:371-379.e2. 2010
    ..Clinical predictive models leave gaps in our ability to stratify cardiovascular risk. High-throughput molecular profiling promises to improve risk classification...
  55. doi request reprint Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial
    Manesh R Patel
    Duke University, Durham, North Carolina 27710, USA
    JACC Cardiovasc Imaging 3:52-60. 2010
    ..The purpose of the study was to understand determinants of infarct size in a primary percutaneous intervention (PCI) population treated with pexelizumab compared with placebo...
  56. doi request reprint Adherence to medication according to sex and age in the CHARM programme
    Bradi B Granger
    Duke University Health System, Duke University School of Nursing, Durham, NC 27710, USA
    Eur J Heart Fail 11:1092-8. 2009
    ..Although many patients with heart failure have incomplete adherence to prescribed medications, predisposing factors remain unclear. This analysis investigates factors associated with adherence, with particular emphasis on age and sex...
  57. pmc Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27707, USA
    Eur Heart J 30:2019-28. 2009
    ..To assess the incidence and timing of atrial fibrillation (AF), describe antithrombotic therapy use, and evaluate the association of AF with 90 day mortality and other secondary clinical outcomes...
  58. doi request reprint Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention
    Rajendra H Mehta
    Duke Clinical Research Institute, Box 17969, Durham, NC 27715, USA
    JAMA 301:1779-89. 2009
    ....
  59. doi request reprint Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study)
    Manesh R Patel
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 103:181-6. 2009
    ..In conclusion, in this observational analysis of stent use from a large primary percutaneous intervention for acute MI trial, DESs appear as safe as BMSs with similar 6-month clinical outcomes with regard to death and recurrent MI...
  60. pmc ALOX5AP variants are associated with in-stent restenosis after percutaneous coronary intervention
    Svati H Shah
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States
    Atherosclerosis 201:148-54. 2008
    ..There is no accurate way to predict in-stent restenosis, although risk factors for atherosclerosis overlap those for in-stent restenosis. Therefore, we evaluated atherosclerosis candidate genes for association with in-stent restenosis...
  61. doi request reprint Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues
    E Marc Jolicoeur
    Duke University, Durham, NC, USA
    Am Heart J 155:435-44. 2008
    ..The present part reviews the current status of understanding of advanced CAD, the limits of contemporary therapies, and the difficulties in and barriers to the development of new treatments...
  62. doi request reprint Sensible approaches for reducing clinical trial costs
    Eric L Eisenstein
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Clin Trials 5:75-84. 2008
    ..Over the past decade, annual funding for biomedical research has more than doubled while new molecular entity approvals have declined by one third...
  63. doi request reprint Do we need to adjudicate major clinical events?
    Christopher B Granger
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715 7969, USA
    Clin Trials 5:56-60. 2008
    ..The purpose of this manuscript is to review the reasons for central adjudication and to discuss whether trials could be simplified by limiting or streamlining the adjudication process...
  64. ncbi request reprint International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes
    Sunil V Rao
    The Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 101:25-29. 2008
    ....
  65. ncbi request reprint Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy
    Jeffrey S Berger
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 117:192-9. 2008
    ..We therefore compared the acute mortality and bleeding risks associated with the initial use of 162 versus 325 mg aspirin in fibrinolytic-treated ST-elevation myocardial infarction patients...
  66. ncbi request reprint Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank
    G Michael Felker
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 50:40-7. 2007
    ..The goal of this study was to identify potentially novel laboratory markers of risk in chronic heart failure patients...
  67. ncbi request reprint Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock
    Rajendra H Mehta
    Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 99:793-6. 2007
    ..This information may help physicians in deciding treatment options for patients with cardiogenic shock and counseling them about their risks...
  68. ncbi request reprint Paramedic transtelephonic communication to cardiologist of clinical and electrocardiographic assessment for rapid reperfusion of ST-elevation myocardial infarction
    David G Strauss
    School of Medicine, Duke University, Durham, NC, USA
    J Electrocardiol 40:265-70. 2007
    ....
  69. doi request reprint Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Contemp Clin Trials 32:178-87. 2011
    ..Independent adjudication of clinical trial events is traditionally performed by physicians on a clinical event classification (CEC) committee...
  70. ncbi request reprint Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials
    Mauricio G Cohen
    Division of Cardiology, University of North Carolina at Chapel Hill, 130 Mason Farm Road, CB 7075, Bioinformatics Building Suite 4128, Chapel Hill, NC 27599, USA
    Am J Med 118:482-8. 2005
    ..To correlate pulmonary artery catheterization (PAC) use and 30-day outcomes and to characterize the use of pulmonary artery catheters among patients with acute coronary syndromes (ACS)...
  71. ncbi request reprint Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation
    Rajendra H Mehta
    Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor 48105, USA
    Am J Cardiol 92:1031-6. 2003
    ..However, only new-onset AF is an independent predictor of in-hospital adverse events in patients with ACS...
  72. pmc A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD Study
    Elizabeth R Hauser
    Center for Human Genetics, Duke University Medical Center, Durham, NC 27710, USA
    Am J Hum Genet 75:436-47. 2004
    ..These data provide initial areas of the human genome where further investigation may reveal susceptibility genes for early-onset CAD...
  73. ncbi request reprint Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circulation 108:1176-83. 2003
    ..The COMPLY trial is reported here...
  74. ncbi request reprint Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes
    Sunil V Rao
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    Am J Cardiol 91:936-40. 2003
    ..This suggests that these patients should be admitted to the hospital and monitored in either an intensive care or step-down unit...
  75. ncbi request reprint Pexelizumab: a novel therapy for myocardial ischemia-reperfusion
    Manesh R Patel
    Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Drugs Today (Barc) 41:165-70. 2005
    ....
  76. ncbi request reprint Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment
    Maria Cecilia Bahit
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am Heart J 143:205-16. 2002
    ..The purpose of this review is to examine the high-risk period for clinical thrombotic events that extends for several weeks after presentation and to review the treatments aimed at reducing these events...
  77. ncbi request reprint Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes
    Sunil V Rao
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 292:1555-62. 2004
    ..It is unclear if blood transfusion in anemic patients with acute coronary syndromes is associated with improved survival...
  78. doi request reprint Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Box 17969, Durham, NC 27715, USA
    Eur Heart J 29:880-7. 2008
    ....
  79. ncbi request reprint Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy
    Trip J Meine
    Division of Cardiology, Department of Medicine, Duke University, Durham, NC 27715, USA
    Am Heart J 149:670-4. 2005
    ..We sought to delineate predictors of AVB and determine long-term mortality of patients developing AVB in the setting of ST-segment elevation MI (STEMI) treated with thrombolytic therapy...
  80. ncbi request reprint Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone
    J Conor O'Shea
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 90:1374-7. 2002
  81. doi request reprint Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation
    R D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27707, USA
    Heart 94:867-73. 2008
    ....
  82. ncbi request reprint Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial
    K W Mahaffey
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 34:1711-20. 1999
    ..The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial was designed to test the hypothesis that adenosine as an adjunct to thrombolysis would reduce myocardial infarct size...
  83. ncbi request reprint Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes
    M T Roe
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Eur Heart J 25:313-21. 2004
    ..To study the relationship between outcomes and peak creatine kinase (CK)-MB levels after percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS)...
  84. ncbi request reprint Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study
    Frederick A Spencer
    Department of Medicine Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Ann Intern Med 140:857-66. 2004
    ..Statins administered early in patients with acute coronary syndromes may lead to modest reductions in recurrent ischemic events...
  85. ncbi request reprint The Editor's Roundtable: arterial thrombosis and acute coronary syndromes
    Vincent E Friedewald
    Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, Texas, USA
    Am J Cardiol 100:974-80. 2007
  86. ncbi request reprint Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab
    Christophe L Dubois
    Department of Cardiology, University Hospitals Leuven, Leuven, Belgium
    J Am Coll Cardiol 42:1178-85. 2003
    ..The aim of this study was to evaluate percutaneous coronary intervention (PCI) in the Assessment of the Safety and Efficacy of New Thrombolytic Regimens (ASSENT-3) trial...
  87. ncbi request reprint Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial
    Shamir R Mehta
    Department of Medicine, McMaster University and Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada
    J Am Coll Cardiol 50:1742-51. 2007
    ..This study reports a prospectively planned analysis of patients with acute coronary syndrome who underwent early percutaneous coronary intervention (PCI) in the OASIS-5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial...
  88. ncbi request reprint International differences in evolution of early discharge after acute myocardial infarction
    Padma Kaul
    University of Alberta, Edmonton, Alberta, Canada
    Lancet 363:511-7. 2004
    ..We aimed to identify the extent to which countries have taken advantage of the opportunity for early discharge...
  89. doi request reprint The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm
    Anna Helgadottir
    deCODE Genetics, Sturlugata 8, IS 101 Reykjavik, Iceland
    Nat Genet 40:217-24. 2008
    ..These findings extend our insight into the role of the sequence variant tagged by rs10757278-G and show that it is not confined to atherosclerotic diseases...
  90. ncbi request reprint Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 116:1482-7. 2007
    ....
  91. ncbi request reprint Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?
    Frederick A Spencer
    Department of Medicine, McMaster University, Faculty of Health Sciences, 1200 Main St W, Hamilton, Canada, L8N 3Z5
    Circulation 116:2793-801. 2007
    ..Because these data are not generalizable to all patients with acute myocardial infarction, we sought to better understand the scope of this problem in a "real-world" setting...
  92. ncbi request reprint Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options
    William E Boden
    School of Medicine and Biomedical Sciences, State University of New York, and Kaleida Health System, Buffalo, New York, USA
    J Am Coll Cardiol 50:917-29. 2007
    ..Results from ongoing clinical trials will provide guidance regarding the utility of this strategy...
  93. ncbi request reprint Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes
    Cheuk Kit Wong
    Cardiovascular Research Unit, Green Lane Hospital, Auckland, New Zealand
    J Am Coll Cardiol 46:29-38. 2005
    ....
  94. ncbi request reprint A common variant on chromosome 9p21 affects the risk of myocardial infarction
    Anna Helgadottir
    deCODE Genetics, Sturlugata 8, IS 101 Reykjavik, Iceland
    Science 316:1491-3. 2007
    ..64 times as great as that of noncarriers. The corresponding risk is 2.02 times as great for early-onset cases. The population attributable risk is 21% for MI in general and 31% for early-onset cases...
  95. ncbi request reprint The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes
    Stefano Savonitto
    Department of Cardiology, Niguarda Hospital, Milan, Italy
    J Am Coll Cardiol 39:22-9. 2002
    ..The study investigated the relationship among creatine kinase (CK) elevations, clinical characteristics and cardiac events across the whole spectrum of acute coronary syndromes (ACS)...
  96. ncbi request reprint Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability
    Rajendra H Mehta
    University of Michigan, Ann Arbor, Michigan 48109, USA
    J Am Coll Cardiol 40:1034-40; discussion 1041-3. 2002
    ..This study evaluated clinical outcomes in patients with acute myocardial infarction (MI) treated with fibrinolytic therapy in hospitals with and without coronary revascularization capability...
  97. ncbi request reprint Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials
    David Hasdai
    Rabin Medical Center, Petah Tikva, Israel
    Am Heart J 145:73-9. 2003
    ..Our objective was to determine the incidence, timing, and consequences of mild-to-moderate HF complicating acute MI...
  98. ncbi request reprint Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study
    Lars Wallentin
    Department of Medical Sciences, Cardiology, University Hospital, S 751 85, Uppsala, Sweden
    Eur Heart J 24:897-908. 2003
    ..We compared the effects of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) as an adjunct to recombinant tissue-plasminogen activator (alteplase) on coronary artery patency and clinical outcomes in AMI...
  99. ncbi request reprint The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2
    Michael C Tjandrawidjaja
    Department of Medicine, Division of Cardiology, 2 51 Medical Sciences Building, University of Alberta, Edmonton, Alberta, Canada
    Eur Heart J 24:1024-34. 2003
    ..To assess gender differences in patients with early reinfarction after fibrinolysis for acute myocardial infarction (AMI) and the impact of these differences on treatment and outcomes...
  100. ncbi request reprint From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE)
    Keith A A Fox
    Department of Cardiology, The Royal Infirmary of Edinburgh, University of Edinburgh, Edinburgh EH3 9YW, Scotland, UK
    Eur Heart J 24:1414-24. 2003
    ..The gap between evidence and practice is well recognized but the factors influencing this disjunction, and the extent to which such factors are modifiable, remain uncertain...
  101. ncbi request reprint Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Lancet 362:759-66. 2003
    ..Patients with chronic heart failure (CHF) are at high risk of cardiovascular death and recurrent hospital admissions. We aimed to find out whether the use of an angiotensin-receptor blocker could reduce mortality and morbidity...